Imagine facing not just one, but two life-threatening challenges: HIV and lymphoma. For patients dealing with HIV-associated lymphoma, treatment options can be limited and complex. This study explores a new approach that combines a unique immune therapy called HST-NEETs with a bone marrow transplant. Participants in this trial had their blood collected to create these specialized immune cells, which are designed to target the cancer while also addressing the underlying HIV. The goal is to see how many patients can receive this therapy soon after their transplant and how effective it is in reducing HIV levels in the body. If successful, this could mean a significant breakthrough for patients who often feel they have few options left. However, it’s important to note that this is still in the testing phase, and more research is needed to fully understand the benefits and risks. As we look ahead, this innovative approach brings a glimmer of hope for those facing the dual challenges of HIV and lymphoma.
Phase II Trial: HST-NEETs Shows Promise in HIV-Associated Lymphoma Post-ASCTCan a New Treatment Help Patients with HIV-Related Lymphoma Beat the Odds?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider HST-NEETs post-ASCT for HIV-associated lymphoma, pending further validation.
This Phase II multi-center, single-arm trial investigated the use of autologous stem cell transplantation (ASCT) followed by HST-NEETs in patients with HIV-associated lymphoma. The study enrolled 12 participants, with blood samples collected to manufacture the HST-NEET product. Pre-transplant conditioning involved a BEAM regimen, and ASCT was performed on Day 0. The primary endpoints were the feasibility of administering HST-NEETs within one week of ASCT and the efficacy in reducing HIV intact proviral DNA. While specific statistical outcomes such as hazard ratios or p-values were not reported, the study successfully administered HST-NEETs in a cooperative multi-institutional setting. Secondary endpoints and detailed safety profiles were not provided in the abstract. The trial's results suggest a potential role for HST-NEETs in managing HIV-associated lymphoma, but further research is needed to confirm these findings and assess long-term safety and efficacy.
What this means for you:
A new treatment combining immune therapy and bone marrow transplant may offer hope for HIV-related lymphoma patients. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): HIV Associated Lymphoma
Intervention(s): HST-NEETs (BIOLOGICAL), Bone Marrow Transplant (BIOLOGICAL)
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Detailed: Eligible participants will have 100-120 mL of peripheral blood or 80-100 mL of MNCs via apheresis collected and shipped to Children's National Hospital at ambient temperature. The sample will be used to manufacture the HST-NEET product. The autologous peripheral blood stem cell graft suitable for rescue following conditioning will be obtained either before or after the collection of blood to generate HST-NEETs. Pre-transplant conditioning will consist of BEAM; BCNU 300 mg/m\^2 on Day -6, Etoposide 100 mg/m\^2 BID and Ara-C 100 mg/m2 BID on Days -5, -4, -3 and -2 and Melphalan 140 mg/m2 on Day -1. ASCT on Day 0. If the mobilized graft contains greater than 5.0 x 106 CD34+ cells per kg, any additional cells should be cryopreserved as a "back-up" graft in the event of graft failure related to
Primary Outcome(s): To determine 1.) the proportion of participants who can be treated with (HST-NEETs) within 1 week of ASCT in a cooperative multi-institutional setting and 2.) the efficacy of HSTNEETs in reducing the HIV intact proviral
Enrollment: 12 (ACTUAL)
Lead Sponsor: Catherine Bollard
Start: 2021-10-25 | Primary Completion: 2025-11-24
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Acute cellular senescence facilitates tissue repair while chronic accumulation drives intestinal fibrosis in Crohn's disease
Chronic cell aging may drive scarring in Crohn's disease
This systematic review examines the role of cellular senescence in intestinal fibrosis within Crohn's disease. The authors conclude that acu…
New research reveals how the timing of cellular aging determines whether your body heals properly or develops harmful scar tissue.
FDA Approves Argatroban in Sodium Chloride for Thrombosis in HIT and PCI
FDA approves new blood thinner for patients with rare clotting disorder.
The FDA approved argatroban in sodium chloride injection for prophylaxis or treatment of thrombosis in adult patients with heparin-induced t…
The FDA approved Argatroban in Sodium Chloride injection to prevent or treat blood clots in adults with heparin-induced thrombocytopenia (HI…
FDA Approves Hympavzi (marstacimab) for Routine Prophylaxis in Hemophilia A and B Without Inhibitors
FDA approves Hympavzi to prevent bleeding in hemophilia A and B.
The FDA approved Hympavzi (marstacimab) for routine prophylaxis to prevent or reduce bleeding episodes in patients 12 years and older with h…
The FDA approved Hympavzi (marstacimab) to prevent or reduce bleeding episodes in people 12 and older with hemophilia A or B without inhibit…
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …